Email Alert RSS
Volume 11 Issue 3
May  2020
Turn off MathJax
Article Contents
Article Navigation >  Medical Journal of Peking Union Medical College Hospital  > 2020  >  11(3): 252-257
Dong XU, Feng-chun ZHANG. Systemic Lupus Erythematosus, Human Papilloma Virus Infection and Vaccine[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 252-257. doi: 10.3969/j.issn.1674-9081.20200042
Citation: Dong XU, Feng-chun ZHANG. Systemic Lupus Erythematosus, Human Papilloma Virus Infection and Vaccine[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 252-257. doi: 10.3969/j.issn.1674-9081.20200042
shu

Systemic Lupus Erythematosus, Human Papilloma Virus Infection and Vaccine

doi: 10.3969/j.issn.1674-9081.20200042

  • Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information
  • Corresponding author: ZHANG Feng-chun  Tel: 86-10-69158792, E-mail:zhangfccra@aliyun.com
  • Received Date: 2020-02-21
  • Publish Date: 2020-05-30
    Abstract
  • Human papilloma virus(HPV)can cause pre-malignant cervical abnormalities and cervical cancer as well as benign conditions such as anogenital warts, especially serotype 16 and 18, which were closely associated with cervical cancer. The prevalence of HPV infection and multiple HPV infections in patients with systemic lupus erythematosus(SLE) is higher than general population, and the risk of abnormal Pap smears and cervical high grade intraepithelial lesions are significantly increased. It is very important to prevent HPV infection in patients with SLE. Vaccine is one of the most effective tools to prevent the infectious diseases. Three non-live protein subunit vaccines for HPV were approved in the last decade:bivalent(HPV 16, 18), quadri-valent(HPV 6, 11, 16, 18), and 9 valent(HPV 6, 11, 16, 18, 31, 33, 45, 52, 58) vaccines. These vaccines were developed to prevent pre-malignant cervical and cervical cancer. qHPV and 9 valent vaccines also prevent benign conditions caused by HPV, such as anogenital warts. Multiple prospective studies showed HPV vaccines were safe and efficacious in patients with SLE, and protective immune response could be produced. In 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases(AⅡRD), it is recommended that patients with AⅡRD, in particular patients with SLE, should receive vaccinations against HPV in accordance with recommendations for the general population.
    • FullText(HTML)
  • loading
    • References(38)
  • [1] Tam LS, Chan AY, Chan PK, et al. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus:association with human papillomavirus infection[J]. Arthritis Rheum, 2004, 50:3619-3625. doi:  10.1002/art.20616
    [2] Furer V, Rondaan C, Heijstek M, et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AⅡRD):a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AⅡRD[J]. RMD Open, 2019, 5:e001041. doi:  10.1136/rmdopen-2019-001041
    [3] Klumb EM, Pinto AC, Jesus GR, et al. Are women with lupus at higher risk of HPV infection?[J].Lupus, 2010, 19:1485-1491. doi:  10.1177/0961203310372952
    [4] Amaral JL, Araújo MV, Dias GA, et al. Clinical and epidemiological study of human papillomavirus infection in women with systemiclupus erythematosus in eastern brazilian amazon[J].Acta Reumatol Port, 2017, 42:47-54. http://europepmc.org/abstract/MED/27750272
    [5] Lyrio LD, Grassi MF, Santana IU, et al. Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus[J]. Rheumatol Int, 2013, 33:335-340. doi:  10.1007/s00296-012-2426-0
    [6] García-Carrasco M, Mendoza-Pinto C, Rojas-Villarraga A, et al. Prevalence of cervical HPV infection in women with systemic lupus erythematosus:A systematic review and meta-analysis[J]. Autoimmun Rev, 2019, 18:184-191. doi:  10.1016/j.autrev.2018.09.001
    [7] Raposo A, Tani C, Costa J, et al. Human papillomavirus infection and cervical lesions in rheumatic diseases:a systematic review[J]. Acta Reumatol Port, 2016, 41:184-190. https://www.ncbi.nlm.nih.gov/pubmed/27682966
    [8] Zard E, Arnaud L, Mathian A, et al. Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus:A metaanalysis of the literature[J]. Autoimmun Rev, 2014, 13:730-735. doi:  10.1016/j.autrev.2014.03.001
    [9] Grein IH, Groot N, Lacerda MI, et al. HPV infection and vaccination in Systemic Lupus Erythematosus patients:what we really should know[J]. Pediatr Rheumatol Online J, 2016, 14:12. doi:  10.1186/s12969-016-0072-x
    [10] Bateman H, Yazici Y, Leff L, et al. Increased cervical dysplasia in intravenous cyclophosphamide-treated patients with SLE:a preliminary study[J]. Lupus, 2000, 9:542-544. doi:  10.1177/096120330000900711
    [11] Yu SL, Chan PK, Wong CK, et al. Antagonist-mediated down-regulation of toll-like receptors increases the preval-ence of human papillomavirus infection in systemic lupus erythematosus[J]. Arthritis Res Ther, 2012, 14:R80. doi:  10.1186/ar3803
    [12] Feldman CH, Liu J, Feldman S, et al. Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Women with Systemic Lupus Erythematosus Receiving Immunosuppressive Drugs[J]. Lupus, 2017, 26:682-689. doi:  10.1177/0961203316672928
    [13] Santana IU, Gomes Ado N, Lyrio LD, et al.Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions:a systematic review[J]. Clin Rheumatol, 2011, 30:665-672. doi:  10.1007/s10067-010-1606-0
    [14] Shi LH, Huang JY, Liu YZ, et al.Risk of systemic lupus erythematosus in patients with human papillomavirus infection:a population-based retrospective cohort study[J]. Lupus, 2018, 27:2279-2283. doi:  10.1177/0961203318809179
    [15] Kanduc D. Quantifying the possible cross-reactivity risk of an HPV16 vaccine[J]. J Exp Ther Oncol, 2009, 8:65-76. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=0556df4ad8e86aaab985bd8e3d696a7f
    [16] Natale C, Giannini T, Lucchese A, et al. Computer-assisted analysis of molecular mimicry between human papillomavirus 16 E7 oncoprotein and human protein sequences[J]. Immunol Cell Biol, 2000, 78:580-585. doi:  10.1046/j.1440-1711.2000.00949.x
    [17] Segal Y, Dahan S, Calabro M, et al. HPV and systemic lupus erythematosus:a mosaic of potential crossreactions[J]. Immunol Res, 2017, 65:564-571. doi:  10.1007/s12026-016-8890-y
    [18] World Health Organization.Electronic address:sageexec-sec@who.int.Human papillomavirus vaccines:WHO position paper, May 2017-recommendations[J].Vaccine, 2017, 35:5753-5755.
    [19] Meites E, Szilagyi PG, Chesson HW, et al. Human Papillomavirus Vaccination for Adults:Updated Recommendations of the Advisory Committee on Immunization Practices[J]. MMWR Morb Mortal Wkly Rep, 2019, 68:698-702. doi:  10.15585/mmwr.mm6832a3
    [20] 中华预防医学会妇女保健分会.子宫颈癌综合防控指南[M].北京:人民卫生出版社, 2017:37-40.
    [21] Drolet M, Bénard É, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes:a systematic review and meta analysis[J]. Lancet Infect Dis, 2015, 15:565-580. doi:  10.1016/S1473-3099(14)71073-4
    [22] Lehtinen M, Lagheden C, Luostarinen T, et al. Ten-year follow-up of human pappillomavirus vaccine efficacy against the most stringent cervicalneoplasia end-point-registry-based follow-up of three cohorts from randomized trials[J]. BMJ Open, 2017, 7:e015867. doi:  10.1136/bmjopen-2017-015867
    [23] Mok CC, Ho LY, Fong LS, et al. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus:a case-control study[J]. Ann Rheum Dis, 2013, 72:659-664. doi:  10.1136/annrheumdis-2012-201393
    [24] Mok CC, Ho LY, To CH.Long-term immunogenicity of a quadrivalent human papillomavirus vaccine in systemic lupus erythematosus[J]. Vaccine, 2018, 36:3301-3307. doi:  10.1016/j.vaccine.2018.04.056
    [25] Soybilgic A, Onel KB, Utset T, et al. Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years[J]. Pediatr Rheumatol Online J, 2013, 11:29. doi:  10.1186/1546-0096-11-29
    [26] Heijstek MW, Scherpenisse M, Groot N, et al. Immuno-genicity of the bivalent human papillomavirus vaccine in adolescents withjuvenile systemic lupus erythematosus or juvenile dermatomyositis[J]. J Rheumatol, 2013, 40:1626-1627. doi:  10.3899/jrheum.130246
    [27] Dhar JP, Essenmacher L, Dhar R, et al.The effect of history of abnormal pap smear or preceding HPV infection on the humoral immune response to Quadrivalent Human Papilloma virus (qHPV) vaccine in women with systemic lupus erythematosus[J]. Hum Vaccin Immunother, 2018, 14:2318-2322. doi:  10.1080/21645515.2018.1469592
    [28] Arnheim-Dahlstrom L, Pasternak B, Svanstrom H, et al. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden:cohort study[J]. BMJ, 2013, 347:f5906. doi:  10.1136/bmj.f5906
    [29] Israeli E, Agmon-Levin N, Blank M, et al. Adjuvants and autoimmunity[J]. Lupus, 2009, 18:1217-1225. doi:  10.1177/0961203309345724
    [30] Bragazzi NL, Bridgewood C, Sharif K, et al. HPV vaccines and lupus:current approaches towards preventing adverse immune cross-reactivity[J]. Expert Rev Vaccines, 2019, 18:31-42. doi:  10.1080/14760584.2019.1557519
    [31] Geier DA, Geier MR. Quadrivalent human papillomavirus vaccine and autoimmune adverse events:a case-control assessment of the vaccine adverse event reporting system (VAERS) database[J]. Immunol Res, 2017, 65:46-54. doi:  10.1007/s12026-016-8815-9
    [32] Soldevilla HF, Briones SF, Navarra SV. Systemic lupus erythematosus following HPV immunization or infection?[J].Lupus, 2012, 21:158-161. doi:  10.1177/0961203311429556
    [33] Miranda S, Chaignot C, Collin C, et al. Human papillomavirus vaccination and risk of autoimmune diseases:A large cohort study of over 2million young girls in France[J]. Vaccine, 2017, 35:4761-4768. doi:  10.1016/j.vaccine.2017.06.030
    [34] Chao C, Klein NP, Velicer CM, et al.Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine[J]. J Intern Med, 2012, 271:193-203. doi:  10.1111/j.1365-2796.2011.02467.x
    [35] Dhar JP, Essenmacher L, Dhar R, et al. The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus[J]. Vaccine, 2017, 35:2642-2646. doi:  10.1016/j.vaccine.2017.04.001
    [36] Genovese C, LA Fauci V, Squeri A, et al. HPV vaccine and autoimmune diseases:systematic review and meta-analysis of the literature[J]. J Prev Med Hyg, 2018, 59:E194-E199. http://www.researchgate.net/publication/328779437_HPV_vaccine_and_autoimmune_diseases_systematic_review_and_meta-analysis_of_the_literature
    [37] Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome[J]. Ann Rheum Dis, 2017, 76:476-485. doi:  10.1136/annrheumdis-2016-209770
    [38] Furer V, Rondaan C, Heijstek MW, et al.2019 update of EULAR recommendation for vaccination in adult patients with autoimmune inflammatory rheumatic diseases[J]. Ann Rheum Dis, 2020, 79:39-52. doi:  10.1136/annrheumdis-2019-215882
    • Relative Articles(0)
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (297) PDF downloads(88) Cited by()
    Proportional views
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return